Bank of Montreal Can boosted its stake in shares of Affimed NV (NASDAQ:AFMD) by 7.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 271,832 shares of the biopharmaceutical company’s stock after acquiring an additional 18,977 shares during the quarter. Bank of Montreal Can owned approximately 0.36% of Affimed worth $1,251,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the business. Mackenzie Financial Corp bought a new position in shares of Affimed in the 1st quarter valued at about $26,000. BNP Paribas Arbitrage SA grew its stake in shares of Affimed by 165.8% in the first quarter. BNP Paribas Arbitrage SA now owns 22,702 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 14,162 shares in the last quarter. GSA Capital Partners LLP boosted its position in Affimed by 110.6% during the first quarter. GSA Capital Partners LLP now owns 23,226 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,196 shares during the period. Citigroup Inc. boosted its position in Affimed by 25.6% during the first quarter. Citigroup Inc. now owns 25,917 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 5,285 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of Affimed by 12,430.8% during the first quarter. Royal Bank of Canada now owns 26,816 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 26,602 shares in the last quarter. 64.19% of the stock is currently owned by hedge funds and other institutional investors.
AFMD has been the subject of a number of analyst reports. SVB Leerink boosted their price target on Affimed from $7.00 to $8.00 and gave the company an “outperform” rating in a research note on Wednesday, June 24th. Zacks Investment Research cut Affimed from a “buy” rating to a “hold” rating in a report on Wednesday, July 1st. BidaskClub upgraded Affimed from a “sell” rating to a “hold” rating in a report on Friday, August 21st. Finally, Laidlaw restated a “buy” rating and set a $10.00 price target on shares of Affimed in a report on Sunday, August 9th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Affimed has an average rating of “Buy” and an average target price of $7.67.
Shares of Affimed stock opened at $3.58 on Wednesday. Affimed NV has a 1 year low of $1.42 and a 1 year high of $4.91. The firm has a market cap of $274.46 million, a PE ratio of -5.11 and a beta of 2.47. The stock has a fifty day moving average price of $3.59 and a 200-day moving average price of $3.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.93 and a quick ratio of 2.91.
Affimed (NASDAQ:AFMD) last issued its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Affimed had a negative return on equity of 133.60% and a negative net margin of 315.16%. The company had revenue of $3.23 million during the quarter, compared to the consensus estimate of $6.79 million. As a group, equities analysts anticipate that Affimed NV will post -0.49 EPS for the current fiscal year.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Story: Quantitative Easing
Want to see what other hedge funds are holding AFMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Affimed NV (NASDAQ:AFMD).
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.